Mode
Text Size
Log in / Sign up
N/A N=50 Treatment

Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant System

Sensorineural Hearing Loss

Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Sep 2014
Primary outcome: Primary: Consonant Nucleus Consonant (CNC) Monosyllabic Word Score-Treated Ear (CO-PRIMARY) — 65.4 percentage of words correct

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Nucleus Hybrid L24 (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Cochlear
Primary completion
Jun 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Consonant Nucleus Consonant (CNC) Monosyllabic Word Score-Treated Ear (CO-PRIMARY)
65.4
PRIMARY
AzBio Sentence Score in Noise - Treated Ear (Co-Primary)
49.2
SECONDARY
Consonant Nucleus Consonant (CNC) Monosyllabic Words - Treated Ear
96
SECONDARY
AzBio Sentence Score-Treated Ear
89.9

Summary

The purpose of this study is to evaluate the safety and efficacy associated with the provision of acoustic and electric sound processing to individuals who demonstrate significant residual low-frequency hearing and profound high-frequency (above 1500 Hz) sensorineural hearing loss. Delivery of acoustic-electric stimulation will be provided by the Nucleus Hybrid L24 cochlear implant system.

Eligibility Criteria

Inclusion Criteria

  • Eighteen years of age or older at the time of implantation.
  • Severe to profound (a threshold average of 2000, 3000, & 4000 Hz > 75dB HL) sensorineural hearing loss for frequencies > 1500 Hz. Low-frequency thresholds up to and including 500 Hz should be no poorer than 60 dB HL.
  • Consonant Nucleus Consonant (CNC) monosyllabic word recognition score (mean of two lists) between 10% and 60%, inclusive (i.e., 10% <= score <= 60%), in the ear to be implanted.
  • CNC word recognition score in the contralateral ear equal to, or better than, the ear to be implanted but not more than 80%.
  • English spoken as a primary language.

Exclusion Criteria

  • Duration of severe-to-profound hearing loss greater than 30 years.
  • Congenital hearing loss (for the purpose of this study, onset prior to 2 years-of-age).
  • Medical or psychological conditions that contraindicate undergoing surgery.
  • Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array.
  • Conductive overlay of 15 dB or greater at two or more frequencies, in the range 250 to 1000 Hz.
  • Hearing loss of neural or central origin.
  • Diagnosis of Auditory Neuropathy.
  • Active middle-ear infection.
  • Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices.
  • Unwillingness or inability of the candidate to comply with all investigational requirements.
  • Additional handicaps that would prevent or restrict participation in the audiological evaluations.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00678899). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search